These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30689542)

  • 1. UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors.
    Finnerty BM; Moore MD; Verma A; Aronova A; Huang S; Edwards DP; Chen Z; Seandel M; Scognamiglio T; Du YN; Elemento O; Zarnegar R; Min IM; Fahey TJ
    Endocr Relat Cancer; 2019 Apr; 26(4):411-423. PubMed ID: 30689542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased UCHL1 expression as a cytologic biomarker for aggressive behavior in pancreatic neuroendocrine tumors.
    Moore MD; Finnerty B; Gray KD; Hoda R; Liu YF; Soong L; Beninato T; Rao R; Zarnegar R; Fahey TJ
    Surgery; 2018 Jan; 163(1):226-231. PubMed ID: 29150024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.
    Yu J; Tao Q; Cheung KF; Jin H; Poon FF; Wang X; Li H; Cheng YY; Röcken C; Ebert MP; Chan AT; Sung JJ
    Hepatology; 2008 Aug; 48(2):508-18. PubMed ID: 18666234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer.
    Xiang T; Li L; Yin X; Yuan C; Tan C; Su X; Xiong L; Putti TC; Oberst M; Kelly K; Ren G; Tao Q
    PLoS One; 2012; 7(1):e29783. PubMed ID: 22279545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer detection by ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids.
    Kato N; Yamamoto H; Adachi Y; Ohashi H; Taniguchi H; Suzuki H; Nakazawa M; Kaneto H; Sasaki S; Imai K; Shinomura Y
    World J Gastroenterol; 2013 Mar; 19(11):1718-27. PubMed ID: 23555160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors.
    Kleiman DA; Beninato T; Sultan S; Crowley MJ; Finnerty B; Kumar R; Panarelli NC; Liu YF; Lieberman MD; Seandel M; Evans T; Elemento O; Zarnegar R; Fahey TJ
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4(0 4):S672-9. PubMed ID: 24854489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1.
    Vandamme T; Peeters M; Dogan F; Pauwels P; Van Assche E; Beyens M; Mortier G; Vandeweyer G; de Herder W; Van Camp G; Hofland LJ; Op de Beeck K
    J Mol Endocrinol; 2015 Apr; 54(2):137-47. PubMed ID: 25612765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
    Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
    Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of hypermethylation in promoter region of ubiquitin carboxyl-terminal hydrolase L1 in human esophageal cancer].
    Yan WJ; Guo MZ; Yang YS
    Zhonghua Nei Ke Za Zhi; 2012 May; 51(5):390-3. PubMed ID: 22883340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
    Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
    Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SQSTM1/p62 is a prognostic molecular marker and potential therapeutic target for pancreatic neuroendocrine tumours.
    Song YL; Weng JH; Zhao DC; Zhang JL; Chen YJ; Xu BH
    Endocrine; 2024 Jul; 85(1):407-416. PubMed ID: 38386167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
    Chow Z; Johnson J; Chauhan A; Jeong JC; Castle JT; Izumi T; Weiss H; Townsend CM; Schrader J; Anthony L; Yang ES; Evers BM; Rychahou P
    Cancer Lett; 2024 Aug; 596():216993. PubMed ID: 38801884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRPV6 modulates proliferation of human pancreatic neuroendocrine BON-1 tumour cells.
    Skrzypski M; Kołodziejski PA; Mergler S; Khajavi N; Nowak KW; Strowski MZ
    Biosci Rep; 2016 Aug; 36(4):. PubMed ID: 27450545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
    Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
    Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis.
    Yamana H; Kato K; Kobara H; Fujihara S; Fujita K; Namima D; Fujita N; Kobayashi K; Kamada H; Morishita A; Tsutsui K; Iwama H; Masaki T
    Anticancer Res; 2020 Jan; 40(1):121-132. PubMed ID: 31892560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular alterations in sporadic pancreatic neuroendocrine microadenomas.
    Hadano A; Hirabayashi K; Yamada M; Kawanishi A; Takanashi Y; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
    Pancreatology; 2016; 16(3):411-5. PubMed ID: 26905832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling.
    Tran CG; Scott AT; Li G; Sherman SK; Ear PH; Howe JR
    Surgery; 2021 Jan; 169(1):155-161. PubMed ID: 32611516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma.
    Seliger B; Handke D; Schabel E; Bukur J; Lichtenfels R; Dammann R
    J Transl Med; 2009 Oct; 7():90. PubMed ID: 19857250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.
    Ummanni R; Jost E; Braig M; Lohmann F; Mundt F; Barett C; Schlomm T; Sauter G; Senff T; Bokemeyer C; Sültmann H; Meyer-Schwesinger C; Brümmendorf TH; Balabanov S
    Mol Cancer; 2011 Oct; 10():129. PubMed ID: 21999842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
    Shimada Y; Kudo Y; Maehara S; Matsubayashi J; Otaki Y; Kajiwara N; Ohira T; Minna JD; Ikeda N
    Cancer Sci; 2020 Feb; 111(2):610-620. PubMed ID: 31845438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.